Brokers Offer Predictions for Tilray Inc’s Q1 2025 Earnings (NASDAQ:TLRY)

Tilray Inc (NASDAQ:TLRY) – Research analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for Tilray in a report released on Tuesday, October 8th. Roth Capital analyst W. Kirk now anticipates that the company will post earnings of ($0.10) per share for the quarter, down from their prior forecast of ($0.09). The consensus estimate for Tilray’s current full-year earnings is ($0.16) per share. Roth Capital also issued estimates for Tilray’s FY2025 earnings at ($0.34) EPS.

Tilray (NASDAQ:TLRY) last issued its quarterly earnings data on Thursday, October 10th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. Tilray had a negative net margin of 30.26% and a negative return on equity of 2.63%. The firm had revenue of $200.00 million for the quarter, compared to analyst estimates of $218.70 million. During the same period in the previous year, the firm earned ($0.10) EPS. Tilray’s revenue was up 13.0% on a year-over-year basis.

Tilray Price Performance

Shares of TLRY stock opened at $1.59 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.42 and a current ratio of 2.27. The firm’s 50 day moving average price is $1.76 and its 200-day moving average price is $1.86. Tilray has a one year low of $1.45 and a one year high of $2.97.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Wellington Wealth Strategies LLC. purchased a new position in shares of Tilray in the fourth quarter valued at approximately $29,000. Austin Wealth Management LLC purchased a new stake in shares of Tilray during the fourth quarter worth $115,000. HighPoint Advisor Group LLC purchased a new position in Tilray in the fourth quarter valued at $43,000. Madrona Financial Services LLC purchased a new position in Tilray in the first quarter valued at $124,000. Finally, Sycomore Asset Management purchased a new stake in Tilray during the 1st quarter worth about $73,000. 9.35% of the stock is currently owned by institutional investors and hedge funds.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.